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Abstract
Background: Radiation pneumonitis (RP) is a major pulmonary adverse event of 
chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective sub-
sequent-line therapy after concurrent chemoradiotherapy (CCRT) found that patients 
with grade 2 or higher RP may have to be excluded from treatment under certain 
criteria. The purpose of this study was to investigate the relationship between grade 
≥2 RP and the parameters of dose-volume histograms after CCRT with cisplatin/
docetaxel for stage III non-small cell lung cancer and conduct a subset analysis of se-
vere RP that can lead to the permanent discontinuation of treatment per the PACIFIC 
trial criteria to help determine treatment strategy.
Methods: We calculated the percentage of the lung volume received at least 5 Gy 
(V5) and 20 Gy (V20), the mean lung dose (MLD), and the lung volume spared from 
a 5 Gy dose (VS5) to the total lung volume. Factors affecting the incidence of grade 
≥2 RP were identified; severe RP was defined as grade ≥3 as well as grade 2 RP that 
required ≥10 mg prednisolone for at least 12 weeks.
Results: This study included 45 patients. On univariate analysis, all parameters and 
total lung volume were found to be significant predictors of grade ≥2 RP (P = .001, 
.003, .03, .004, and .02, respectively). On multivariate analysis, V20 was a significant 
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1 |  BACKGROUND
Concurrent chemoradiotherapy (CCRT) is considered one of 
the standard treatments for medically inoperable stage III non-
small cell lung cancer (NSCLC).1-4 The standard chemother-
apy that is administered simultaneously with radiotherapy is 
a platinum/taxane combination. After CCRT with cisplatin/
docetaxel previously showed favorable results,1 this regimen 
has since been the recommended chemotherapy in Japan. 
Radiation pneumonitis (RP) is a major pulmonary adverse 
event that can arise from chest radiotherapy; the incidences of 
grade ≥3 RP ranged between 1.8% and 10.0% in previous pro-
spective studies, while grade 5 RP rates ranged between 0% and 
5.6%.1-4 Several studies have clarified the relationship between 
RP and the parameters of the dose-volume histogram (DVH) 
in patients who underwent CCRT.5-13 These studies found that 
the lung volume percentage received at least 5 Gy (V5) and 
20 Gy (V20), as well as the mean lung dose (MLD), are pre-
dictive factors for RP. Moreover Tsujino et al found that the 
lung volume spared from a 5 Gy dose (VS5)12 was also predic-
tive of RP. Another multicenter investigation revealed that the 
odds ratio of symptomatic RP in patients who received CCRT 
with carboplatin/paclitaxel was as high as 3.33 when compared 
with other chemotherapy regimens.11 RP significantly occurred 
more frequently in patients undergoing CCRT with cisplatin/
docetaxel than in those receiving concurrent cisplatin/vinorel-
bine.8 Although the concurrent administration of taxanes with 
radiotherapy is considered a risk factor for RP, no study (to our 
knowledge) has investigated the correlation between RP and 
DVH parameters in patients with lung cancer that received 
CCRT with a single regimen of cisplatin/docetaxel.
Recently, the breakthrough PACIFIC trial studying the 
administration of durvalumab after CCRT showed that the 
overall and progression-free survival rates were significantly 
higher in patients receiving durvalumab than in those re-
ceiving placebo.14,15 Since patients who develop grade ≥ 2 
RP are no longer eligible for durvalumab, it is crucial to be 
able to predict the occurrence of grades ≥ 2 RP. Moreover 
durvalumab should be discontinued if either grade ≥ 3 RP 
or grade 2 RP that requires >10  mg prednisolone for over 
12 weeks develops.14 However, the incidences of severe RP 
that are produced by each type of chemotherapy regimen, as 
well as factors that predict severe RP, remain unclear.
The aim of this study was to examine the relationship 
between grades ≥ 2 RP and parameters of DVH in patients 
with stage III lung cancer who received definitive CCRT 
with cisplatin/docetaxel and identify predictive factors for the 
same. Furthermore, we determined the rates of severe RP that 
would render patients permanently ineligible for continued 
durvalumab treatment under the criteria of the PACIFIC trial, 
and also identified DVH-related risk factors in patients with 
V20 values <35%.
2 |  METHODS
2.1 | Patients
We retrospectively evaluated patients who received defini-
tive CCRT between January 2004 and May 2018 at the au-
thor's hospital. The inclusion criteria were as follows: stage 
III NSCLC, a radiotherapy dose of 54  Gy/27 fractions to 
66 Gy/33 fractions, cisplatin/docetaxel as concurrent chemo-
therapy regimen, and no reception of neoadjuvant chemother-
apy before the start of radiotherapy. All procedures complied 
with the ethical standards of the 1964 Declaration of Helsinki 
and the subsequent amendments. Written informed consent 
was obtained from all patients prior to treatment. The option 
to opt-out was provided to all patients through notifications 
displayed on the hospital's website and outpatient ward prior 
to the start of this study. The hospital's review board ap-
proved this study.
2.2 | Treatment
Staging was classified according to the 7th edition of the 
TNM classification of malignant tumors. Three-dimensional 
predictive factor of grade ≥2 RP (P = .007). Severe RP developed in 6 of 37 patients 
(16.2%) whose V20 values were 35% or lower. On univariate analysis, only V20 was 
a significant predictor of severe RP in these patients (P = .01).
Conclusions: The best approach to reduce the rate of grade ≥2 RP is to maintain the 
V5, V20, MLD, and VS5 as low as possible during radiotherapy planning in patients 
receiving definitive CCRT with cisplatin/docetaxel.
K E Y W O R D S
cisplatin/docetaxel, dose-volume histogram, non-small cell lung cancer, PACIFIC trial, radiation 
pneumonitis
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conformal radiation therapy (3D-CRT) was performed for 
all patients. Computed tomography (CT) scans for planning 
were performed at 2-10  mm intervals with free-breathing 
without four-dimensional CT scan. The gross tumor volume 
is a combination of the volume of the primary tumor and 
clinically diagnosed metastatic lymph node. The margin of 
clinical target volume was 5-10  mm. When elective nodal 
irradiation was performed, non-metastatic subcarinal and 
ipsilateral hilar nodal stations were included. The attending 
physician decided the internal margin based on fluoroscopic 
images. The margin of planning target volume was 5-10 mm. 
The total dose was 54-66  Gy/27-33 fractions at isocenter 
with 10 MV photon beam generated from a linear accelera-
tor (ONCOR, Primus or Mevatron, Canon Medical Systems, 
Tochigi, Japan). We calculated all plans using the XiO com-
puter software (version 4.8.0, Electa, Stockholm, Sweden) 
with a non-uniformity correction algorithm as a superposi-
tion. The chemotherapy regimen used concurrently with ra-
diotherapy was cisplatin/docetaxel, based on a prospective 
trial of OLCSG 0007.1
2.3 | Statistical analysis and evaluation
Total lung was defined as gross tumor minus both lungs; 
automatic contour extraction was performed using CT-
based thresholds. The RP grade was assigned using the 
Common Toxicity Criteria for Adverse Events (CTCAE) 
version 4.0. As DVH parameters, V5, V20, MLD, and VS5 
were calculated. The relationships between the incidences 
of grades ≥ 2 RP and parameters of DVH were analyzed 
using the log-rank test for univariate analysis and the 
Cox proportional hazard model for multivariate analysis. 
Cutoff values for continuous variables were decided from 
individual receiver operating characteristic (ROC) curves 
before performing the log-rank test. The cutoff values at 
the maximal point of the Youden Index were adopted. The 
associations between total lung volume and DVH param-
eters were tested using the Pearson product-moment cor-
relation coefficient. Severe RP that would cause permanent 
treatment discontinuation according to the PACIFIC trial 
criteria was defined as either grade ≥ 3 or grade 2 that re-
quired the maintenance of >10 mg prednisolone for more 
than 12 weeks.14 Because the V20 of the DVH parameters 
in the PACIFIC trial was below 35%, the rate of severe RP 
was calculated for patients in our study with V20 values 
below 35%. The cumulative incidence rate of RP was cal-
culated using the Kaplan-Meier method; the RP rate was 
also stratified according to significant factors on univari-
ate analysis. Two-tailed P-values of <.05 were considered 
to be significant predictors. All statistical tests were per-
formed using The R software, version 3.2.0 (R Foundation 
for Statistical Computing).
3 |  RESULTS
Table 1 shows the characteristics of the 45 patients who met 
the eligibility criteria. The total dose of radiation therapy was 
60  Gy in 44 patients and 54  Gy in 1 patient. The median 
V5, V20, MLD, VS5, and total lung volume were 41.45% 
T A B L E  1  Patient characteristics
%
Age (years) Median (range) 63 (36-84) –
Sex Male 41 91
Female 4 9
ECOG-PS 0 18 40
1 27 60
Smoking history Never 1 2
Former 19 42
Current 25 56
Lobea Upper 36 80
Lower 8 18
Lateralitya Right 24 53
Left 20 44
Histology Adenocarcinoma 14 31
Squamous cell 
carcinoma
27 60
Non-small cell 
carcinoma
4 9
C-stage IIIA 7 16
IIIB 38 84
FEV1 (l)a Median (range) 2.35 (0.48-4.11) –
FVC (l)a Median (range) 3.32 (1.51-6.35)
%VC (%) Median (range) 96.9 (62.7-159.8)
Total lung volume 
(cm3)
Median (range) 3176.94 
(1979-4833)
–
Tumor size (mm) Median (range) 55.0 (10.0-111.0) –
GTV volume 
(cm3)
Median (range) 167.61 
(128.38-745.31)
–
V5 (%) Median (range) 41.45 
(17.86-72.59)
–
V20 (%) Median (range) 27.48 
(10.10-48.59)
–
MLD (Gy) Median (range) 14.89 
(6.07-22.62)
–
VS5 (cm3) Median (range) 1980.2 
(612.3-3376.5)
–
Abbreviations: %VC, % vital capacity; ECOG-PS, Eastern Cooperative 
Oncology Group performance status; FEV1, forced expiratory volume in 1 s; 
FVC, forced vital capacity; GTV, gross tumor volume; MLD, mean lung dose 
of the lung; V20, percentage of the lung volume received at least 20 Gy; V5, 
percentage of the lung volume received at least 5 Gy; VS5, volume of the lung 
spared from 5 Gy.
aThese factors have missing values. 
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(range: 17.86%-72.59%), 27.48% (range: 10.1%-48.59%), 
14.89  Gy (range: 6.07-22.62  Gy), 1980.24 cm3 (range: 
612.30-3376.51  cm3), and 3176.94  cm3 (range: 1987.64-
4832.98 cm3), respectively. Grades 0, 1, 2, 3, 4, and 5 RP 
developed in 1 (2.2%), 23 (51.1%), 16 (35.6%), 3 (6.7%), 0 
(0.0%), and 2 (4.4%) of the patients, respectively. The median 
follow-up period was 20.0 months (range 2.4-151.8 months).
Figure 1 shows individual ROC curves. In ROC analysis, 
we found that V5, V20, MLD, VS5, and TLV cutoff values 
of 41%, 28%, 15 Gy, 1950 cm3, and 3680 cm3 provided the 
best combination of sensitivity and specificity. Sensitivity/
specificity were 0.762/0.75, 0.714/0.792, 0.81/0.667, 
0.714/0.75, and 0.952/0.417, respectively. Results of uni-
variate and multivariate analyses of factors affecting ≥2 
RP are shown in Table 2. On univariate analysis, the V5, 
V20, MLD, VS5, and total lung volume were significant 
predictors of grade ≥ 2 RP (P = .001, .003, .03, .004, and 
.02, respectively). The absolute Pearson correlation coef-
ficients between V5/V20, V5/MLD, V5/VS5, V20/MLD, 
V20/VS5, MLD/VS5, and VS5/total lung volume were 
0.940, 0.885, 0.732, 0.955, 0.711, 0.706, and 0.753, respec-
tively. In contrast, the correlation coefficients between V5/
F I G U R E  1  Receiver operating 
characteristic curves; (A) the percentage of 
the lung volume that received more than 
5 Gy (V5), (B) the percentage of the lung 
volume that received more than 20 Gy 
(V20), (C) the mean lung dose (MLD), (D) 
the lung volume spared from a 5 Gy dose 
(VS5), and (E) the total lung volume
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total lung volume, V20/total lung volume, and MLD/total 
lung volume were 0.125, 0.155, and 0.186, respectively. 
From among the V5, V20, MLD, and VS5, we selected V20 
for multivariate analysis based on Tsujino et al’s study.12 
On multivariate analysis, V20 was a significant predictor 
(P = .007), whereas total lung volume was not (P = .055) 
on multivariate analysis..
The median duration between the end of definitive CCRT 
and the development of grade  ≥  2 RP was 11.29  weeks 
(range: 1.57-32.57 weeks). The Kaplan-Meier curve for the 
cumulative incidence of grade ≥ 2 RP is shown in Figure 2; 
incidence rates were 42.8% (95% confidence interval [CI]: 
26.2-55.6%) at 6 months and 47.6% (95% CI: 30.5%-60.5%) 
at 12  months. The Kaplan-Meier curves for the cumula-
tive incidence of grade  ≥  2 RP were stratified according 
to the five factors that were significant predictors on uni-
variate analysis are shown in Figure 3. The incidence rates 
of grade  ≥  2 RP after 6  months were as follows: 18.9% 
and 69.6% in patients with V5 values of < 41% and ≥ 41%, 
respectively; 17.8% and 68.2% in patients with V20 val-
ues of <28% and ≥28%, respectively, 22.2% and 63.6% in 
patients with MLDs of <15 Gy and ≥15 Gy, respectively; 
66.7% and 21.1% in patients with VS5 values of <1950 
and ≥1950 cm3, respectively, and 66.7% and 21.1% in pa-
tients with total lung volumes of <3680 and ≥3680  cm3, 
respectively.
Thirty-seven of the 45 patients had a V20 of 35% or less. 
Grades 0, 1, 2, 3, 4, and 5 RP developed in 1 (1.4%), 21 
(56.8%), 12 (32.4%), 2 (5.4%), 0 (0.0%), and one (1.4%) of 
the patients, respectively. Severe RP that would require per-
manent treatment discontinuation according to the PACIFIC 
trial criteria developed in 6 (16.2%) of the 37 patients. The 
V20 cutoff value calculated using the ROC curves was 28.5%; 
on univariate analysis, V20 was the only significant predictor 
of severe RP in this subgroup (P = .01).
T A B L E  2  Univariate analyses of predictive factors related to 
grade ≥ 2 radiation pneumonitis
Factor N
Univariate 
P-value
Multivariate 
P-value
Age (years)
<63 8/20 .3 NE
≥63 13/25
Sex
Male 21/41 .09
Female 0/4 NE
ECOG-PS
0 8/18 .6 NE
1 13/27
Smoking history
Never/Former 10/20 .6 NE
Current 11/25
Lobea 
Lower lobe 4/8 .7 NE
Upper lobe 17/36
Lateralitya 
Right 13/24 .5 NE
Left 8/20
FEV1 (l)a 
<1.7 1/7 .09 NE
≥1.7 17/31
FVC (l)a 
<3.0 9/15 .3 NE
≥3.0 9/23
%VC (%)a 
<99 10/24 .5 NE
≥99 8/14
Total lung volume (cm3)
<3680 20/35 .02 .055
≥3680 1/10
Tumor size (mm)a 
<67 18/32 .1 NE
≥67 3/11
GTV volume (cm3)
<62 13/30 .1 NE
≥62 8/15
V5 (%)
<41 5/22 .001 NE
≥41 16/23
V20 (%)
<28 6/23 .003 .007
≥28 15/22
(Continues)
Factor N
Univariate 
P-value
Multivariate 
P-value
MLD (Gy)
<15 7/23 .03 NE
≥15 14/22
VS5 (cm3)
<1950 15/21 .004 NE
≥1950 6/24
Abbreviations: %VC, % vital capacity; CI, confidence interval; ECOG-PS, 
Eastern Cooperative Oncology Group Performance Status; FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity; GTV, gross tumor volume; 
MLD, mean lung dose of the lung; NE, not entered; V20, percentage of the lung 
volume received at least 20 Gy; V5, percentage of the lung volume received at 
least 5 Gy; VS5, volume of the lung spared from 5 Gy.
aThese variables have missing values. 
T A B L E  2  (Continued)
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4 |  DISCUSSION
Radiation pneumonitis is a noteworthy adverse event in 
patients who have undergone definitive radiotherapy for 
NSCLC; V20 and MLD are major predictors among the vari-
ous DVH parameters. Graham et al found that V20 was a pre-
dictive factor of grades ≥ 2 RP on univariate and multivariate 
analyses5; the incidences of grade ≥ 2 RP at 24 months were 
0%, 8%, 13%, and 36% in patients with V20 values of <22%, 
22%-31%, 32%-40%, and >40%, respectively. Forty-two per-
cent of patients received neoadjuvant or concurrent chemo-
therapy. As the incidence of RP appeared to be elevated with 
concurrent chemotherapy, V20 was related to grade ≥ 2 RP 
after treatment for definitive CCRT, on univariate analysis 
in the study by Tsujino et al6; the 6-month cumulative inci-
dences rates of grade ≥ 2 RP were 14% in those with V20 
values <26% and 63% in those with V20 values ≥26%. Of 
the 71 patients undergoing CCRT in their study, 36 (50.7%) 
received a taxane regimen, 33 of which received carbopl-
atin/paclitaxel. A review of over 70 studies of RP by Marks 
et al revealed that the V20 and MLD were factors related to 
this adverse effect; the V20 threshold for limiting the risk of 
symptomatic RP ≤ 20% was 30-35%.9 The major difference 
between the third and fourth CTCAE versions is mainly the 
use of steroids for grading pneumonitis. Dang et al investi-
gated RP in 369 patients with lung cancer using the CTCAE 
version 4 and found that V20 was a significant predictor as-
sociated with RP on univariate analysis.8 Consistent with 
such previous studies, the V20 was found to be a signifi-
cant predictive factor of RP on univariate and multivariate 
analyses in our study (P = .003 and .007, respectively); the 
cumulative incidence rates of grade ≥ 2 RP after 6 months 
were 17.8% and 68.2% in patients with V20 values <28% 
and ≥28%, respectively. Although the diagnostic criteria and 
cut-off values for RP in our study were different, the rates of 
grade ≥ 2 RP as stratified by V20 was close to that of Tsujino 
et al6
Mean lung dose is a predictive factor of RP in patients 
who received definitive CCRT. In Barriger et al's study, the 
incidence rates of grade ≥ 2 RP were 2.2% and 19% in pa-
tients whose MLDs are <18 and >18 Gy, respectively.7 The 
MLD threshold for maintaining the risk of symptomatic RP 
≤20% was 20-23 Gy.9 In our study, MLD was a significant 
predictive factor of grade  ≥  2 RP on univariate analysis 
(P = .03). Palma et al also presented MLD to be a predic-
tive factor of RP in patients ≤65 years of age who received 
CCRT using carboplatin/paclitaxel chemotherapy, accord-
ing to recursive partitioning analysis; their threshold was 
10 Gy.11 In the study by Dang et al, MLD was found to be 
a predictor for RP on univariate and multivariate analyses8; 
MLD of patients with grade 1 RP was 14.15 ± 3.26 Gy, that 
for patients with grade 2 RP was 17.71 ± 3.28 Gy, and that 
for patients with grades 3-5 RP was 21.4 ± 3.48 Gy. MLDs 
for all patients who developed RP of grades ≥ 2 were, there-
fore, between 17  Gy and 21  Gy. In our study, the MLD 
threshold for developing RP, as obtained from the ROC 
curve, was 15  Gy. Although an accurate comparison was 
not possible because MLD associated with grade  ≥  2 RP 
was unknown, and patients other than those who received 
concurrent chemotherapy were also included in their study, 
our value was close to theirs.
In a previous analysis of 22 patients who received in-
tensity-modulated radiotherapy (IMRT), V5 was found to 
be a prognostic factor for grade ≥ 3 RP.10 The incidence of 
grade ≥ 3 RP RP after 12 months was 2% in patients with 
V5 values ≤70% but was 21% in those with values >70% 
(P = .017). Similarly, V5 was a significant predictor of RP 
on univariate analysis in our study. In Yom et al's study, the 
median V5 was significantly higher in the IMRT group (63%, 
range: 5%-98%) than in the 3D-CRT group (57%, range: 12%-
98%). Moreover the median V20 in the IMRT group (35%, 
range: 3%-48%) was lower than that in the 3D-CRT group 
(38%, range: 8%-78%); the MLDs were not significantly dif-
ferent. The incidence rates of grade ≥ 3 RP after 12 months 
were 8% for patients who received IMRT and 32% for those 
receiving 3D-CRT. It was posited that the decrease in V20 
contributed to a decrease in the incidence of RP. In a random-
ized trial by Liao et al comparing the outcomes of passive 
scattering proton therapy (PSPT) to those of IMRT, PSPT 
resulted in a lower lung V5-10 but higher lung V20-80 than 
did IMRT. The rates of grade ≥ 3 RP did not differ between 
the 2 groups.16 Like in Tsujino et al’s study, V5 correlated 
with other DVH parameters in our study; hence, it is neces-
sary to plan treatments while considering all the parameters. 
Additional research is required to ascertain the effects of low-
dose radiation on the lung and determine the optimal balance 
F I G U R E  2  Cumulative incidence rate of grade ≥ 2 radiation 
pneumonitis after completion of radiotherapy. The dashed lines 
represent the 95% confidence interval
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between the various DVH parameters that minimizes the risk 
of PR caused by CCRT with cisplatin/docetaxel.
Tsujino et al investigated the relationship between RP and 
VS5 and found that a VS5 < 1500 cm3 was a significant pre-
dictive factor of grade ≥ 3 RP.12 The incidences of grade ≥ 3 
PR were 7.3% and 50% for patients in whom the VS5 values 
were ≥1500 and <1500  cm3, respectively. Chen et al also 
showed VS5 to be a predictive factor of grade ≥ 2 RP in pa-
tients treated with IMRT.13 The incidence rate of grade ≥ 2 
RP was significantly lower when VS5 of the ipsilateral lung 
was ≥564.9 cm3 than it was with VS5 values <564.9 cm3. 
VS5 of the ipsilateral lung was a predictor of grade ≥ 2 RP. 
Chen et al’s study demonstrated the importance of the VS5, 
even though they included small cell lung cancer patients; 
moreover, they used the toxicity criteria of the RTOG. In our 
study, VS5 was also found to be a predictor of grade ≥ 2 PR, 
considering that VS5 and other parameters may contribute to 
improving the clinical courses of patients with NSCLC who 
undergo CCRT with cisplatin/docetaxel.
A multicenter study by Palma et al reported that undergo-
ing chemotherapy was a predictive factor for symptomatic RP; 
its odds ratio with carboplatin/paclitaxel relative to cisplatin/
etoposide was 3.33 (P < .001).11 Onishi et al showed that the 
incidence of grade ≥ 3 RP was as high as 47% in patients 
who received weekly docetaxel and 2-dimensional radiother-
apy.17 In Dang et al's study, the incidence rates of grade ≥ 2 
were 39.7%, 31%, and 33.6% in patients who received con-
comitant cisplatin/docetaxel, concomitant cisplatin/vinorel-
bine, and sequential chemotherapy after radiotherapy; the 
corresponding incidence rates of grade ≥ 3 RP were 18.4%, 
9.5%, and 11.2%, respectively.8 The incidence of grade ≥ 3 
RP was higher in the concomitant cisplatin/docetaxel group 
F I G U R E  3  Subgroup analysis of the cumulative incidence rates of grade ≥ 2 radiation pneumonitis after completion of radiotherapy; (A) the 
percentage of the lung volume that received more than 5 Gy (V5), (B) the percentage of the lung volume that received more than 20 Gy (V20), (C) 
the mean lung dose (MLD), (D) the lung volume spared from a 5 Gy dose (VS5), and (E) the total lung volume
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than in the concomitant cisplatin/vinorelbine group. While a 
comparison of RP incidences between Dang et al’s study and 
our study should be performed with caution due to the lack 
of reporting of DVH parameters in their cisplatin/docetaxel 
group, the incidence rate of grade ≥ 2 RP in our study was 
47.6% at 12 months, which was slightly higher than that in 
their study. IMRT was associated with a lower incidence rate 
of grade ≥ 3 RP18; 22% of the patients in their study received 
IMRT, which may explain this result. To our knowledge, ours 
is the first study to show the incidence of grade ≥2 RP and its 
associated DVH parameters in patients undergoing definitive 
CCRT with cisplatin/docetaxel.
Programmed death 1 (PD-l) and PD-1 ligand 1 (PD-L1) 
are important molecules in immune regulation. In compar-
ison with docetaxel, Nivolumab, a PD-1 inhibitor, improved 
OS rates in patients previously treated with squamous-cell 
lung cancer. Pneumonitis is a serious adverse event caused 
by the use of PD-1 inhibitors, leading to the discontinuation 
of cancer therapy, with resultant mortality.19 Durvalumab 
blocks the interaction between PD-L1 and PD-1, but does 
not bind to PD-1 ligand 2 (PD-L2).20 Khunger et al showed 
that the incidence of pneumonitis were 3.6% and 1.3% in the 
PD-1 and PD-L1 inhibitor groups, respectively. The inci-
dence of pneumonitis in patients who received PD-1 inhibi-
tors was significantly higher than that of PD-L1 inhibitors.21 
One reason for the lower rate of pneumonitis in PD-L1 inhib-
itors is the presence of PD-L2. PD-L2 might play an import-
ant role in accommodating immune tolerance in the lungs; 
it interacts with PD-l and is affected by PD-l inhibitors. In 
a study involving murine models, Xiao et al suggested that 
PD-1 blockade may shift the balance of PD-L2 interaction 
with binding partners, and increase the capacity of PD-L2 
binding to repulsive guidance molecule b, which is able to 
lead to pneumonitis.22 Further experimental investigations 
about pneumonitis induced by combination therapy of PD-L1 
inhibitor and radiotherapy are warranted.
Durvalumab cannot be administered if grade  ≥  2 RP 
occurs.14 As such, the management of grade  ≥  2 RP be-
came more urgent after the publication of the PACIFIC 
trial that showed the benefits of durvalumab treatment after 
chemoradiotherapy. In the study by Hosoya et al, 19 of 82 
patients (23%) became ineligible for durvalumab treatment 
(as specified by the PACIFIC trial criteria) after receiving 
CCRT23; of these 19 patients, 6 developed grade  ≥  2 RP 
within 42  days after CCRT. Their study further revealed 
that old age, male sex, and radiotherapy with a V20 ≥ 35% 
were related to durvalumab ineligibility after CCRT. In the 
PACIFIC trial, the hazard ratio for death was 0.42 for patients 
who commenced treatment with durvalumab < 14 days after 
completing CCRT, and was 0.81 for those who commenced 
treatment ≥ 14 days after CCRT.15 These data showed that 
the early introduction of durvalumab was beneficial and that 
physicians do not have to wait 42 days after CCRT before 
administering this agent. Pneumonitis had the highest inci-
dence rate of all adverse events that led to the criteria for 
the discontinuation (4.8% of the patients in the durvalumab 
group and 2.6% of those in the placebo group) and RP (1.3% 
and 1.3%, respectively). Additionally, a criterion for the dis-
continuation of durvalumab in the PACIFIC trial was the 
occurrence of severe grade ≥ 2 RP that required > 10 mg 
prednisolone for more than 12 weeks14; moreover, the V20 
was required to be 35% or lower to avoid the occurrence 
of RP. In our study, severe RP that met the PACIFIC trial's 
abovementioned criterion for permanent discontinuation of 
durvalumab occurred in 6 of 37 patients (16.2%) who had 
V20 values of ≤35%. Only the V20 was a significant pre-
dictive factor of RP on univariate analysis despite the small 
sample size. In the PACIFIC trial, RP of all grades occurred 
in 20.2% of patients who received the durvalumab and 
15.8% of those who received placebo15; hence, durvalumab 
appeared to increase the risk of pneumonitis slightly. 
According to our data, the incidence of severe RP is likely 
to be 16.2% or higher if durvalumab is started immediately 
after the end of CCRT using cisplatin/docetaxel. Because 
details regarding radiotherapy in the PACIFIC trial have not 
yet been published, additional research is required to de-
termine the effects of durvalumab on the lung after CCRT, 
as well as the associated DVH parameters, in patients who 
discontinue treatment.
Grade 5 RP developed in two patients in our study (4.4%). 
In previous prospective trials, the V20 value was not among 
the eligibility criteria. Grade 5 RP occurred in 1.9% of the 
patients undergoing CCRT with carboplatin/paclitaxel in the 
West Japan Thoracic Oncology Group 0105 trial2 and 2.0% 
of those undergoing the same treatment in the OLCSG 0007 
trial.1 In recent prospective trials, the V20 has been limited 
to 35% or less. Two of the 283 patients (0.7%) in the CCRT 
with cisplatin/pemetrexed group of the PROCLAIM study 
died of possible RP, while no grade 5 RP occurred among pa-
tients receiving CCRT plus cisplatin/etoposide.3 Although the 
incidence of grade 5 RP appeared to have decreased slightly 
after restricting the V20 values, grade 5 RP still occurred in 
5.3% and 1.9% of patients administered cisplatin/S-1 and cis-
platin/vinorelbine in the West Japan Oncology Group 5008L 
study of Japanese patients.4 Hence, Japanese patients receiv-
ing CCRT should be monitored for grade 5 RP, as risk factors 
other than the DVH parameters may exist (this requires addi-
tional investigation).
To the best of our knowledge, ours is the first study to 
determine the predictive factors for grade  ≥  2 or severe 
RP that would require permanent treatment discontinuation 
under the PACIFIC trial criteria in patients administered 
CCRT with cisplatin/docetaxel. There were several lim-
itations in our study. First, this was a retrospective anal-
ysis with small sample size. Therefore, more studies with 
more lung cancer patients receiving CCRT with cisplatin/
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docetaxel are needed to confirm the prognostic value of 
V20. Second, assessments of important factors, such as 
single nucleotide polymorphisms and background lung dis-
ease, were not performed. For example, Xu et al24 reported 
that genetic variants of surfactant protein D were associ-
ated with the development of RP. Third, we only evaluated 
RP but not other types of adverse events that could also 
lead to permanent treatment discontinuation according to 
the PACIFIC trial criteria.
5 |  CONCLUSION
V20 is a significant predictor of grade ≥ 2 and severe RP. 
Severe RP that would lead to permanent discontinuation of 
treatment according to the PACIFIC trial criteria developed 
in 16.2% of the patients who received definitive CCRT with 
cisplatin/docetaxel. Detailed future investigations of the rela-
tionship RP and parameters of DVH in patients who receive 
durvalumab as part of a concurrent chemotherapy regimen 
are warranted.
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